Legend Biotech Down Over 14%, on Track for Record Low Close — Data Talk
Legend Biotech Corp. Sponsored ADR (LEGN) is currently at $20.10, down $3.32 or 14.19%
--Would be new all-time closing low (Based on available data back to June 5, 2020)
--On pace for largest percent decrease since Dec. 15, 2021, when it fell 15.25%
--Snaps a two day winning streak
--Down 7.56% month-to-date
--Down 7.56% year-to-date
--Down 73.73% from its all-time closing high of $76.50 on July 28, 2023
--Down 46.33% from 52 weeks ago (Jan. 22, 2025), when it closed at $37.44
--Down 54.66% from its 52-week closing high of $44.32 on July 23, 2025
--Would be a new 52-week closing low
--Traded as low as $19.61; new all-time intraday low (Based on available data back to June 5, 2020)
--Down 16.27% at today's intraday low; largest intraday percent decrease since Dec. 15, 2021, when it fell as much as 18.93%
All data as of 1:56:23 PM ET
Source: Dow Jones Market Data, FactSet
(END) Dow Jones Newswires
January 21, 2026 14:14 ET (19:14 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
4 Stocks to Buy Before They Rise Further
2 Undervalued Stocks to Buy Before They Rebound
The 10 Best Companies to Invest in Now
The 10 Best Dividend Stocks
United States